These strategies highlight the potential of GSH-responsive nanomedicine as part of integrated, multi-modal cancer treatments
In April 2026, the FDA approved the Eli Lilly drug orforglipron (Foundayo), the first non-peptide small-molecule, once-daily oral GLP-1 receptor agonist for weight management
When administered, weight loss injections such as Wegovy help regulate appetite, increase feelings of fullness, and reduce food intake, ultimately leading to weight loss
and the IARC Group 1 carcinogen c-Met red flag and why cleaner air comes first, not a peptide
DSIP helps induce sleep by modulating neurotransmitter activity, making it an effective solution for individuals strugg
Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and meta-analysis